INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 35 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $5,420,332,000 | +3.0% | 8,362,000 | -5.4% | 0.01% | -20.0% |
| Q4 2020 | $5,261,461,000 | -4.9% | 8,837,000 | +9.8% | 0.01% | +25.0% |
| Q3 2020 | $5,532,883,000 | +259.9% | 8,049,000 | +275.6% | 0.01% | +166.7% |
| Q2 2020 | $1,537,388,000 | -15.7% | 2,143,000 | 0.0% | 0.00% | -25.0% |
| Q1 2020 | $1,823,243,000 | +54.8% | 2,143,000 | +140.8% | 0.00% | +100.0% |
| Q4 2019 | $1,177,568,000 | -36.9% | 890,000 | -57.2% | 0.00% | -33.3% |
| Q3 2019 | $1,867,602,000 | +7.1% | 2,078,000 | +17.9% | 0.00% | 0.0% |
| Q2 2019 | $1,744,524,000 | – | 1,763,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PenderFund Capital Management Ltd. | 11,795,000 | $10,081,000 | 2.79% |
| Context Capital Management, LLC | 9,795 | $6,281,000 | 0.45% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $144,000 | 0.02% |
| Calamos Advisors LLC | 5,000,000 | $3,209,000 | 0.01% |
| FRANKLIN RESOURCES INC | 21,000,000 | $13,885,000 | 0.01% |
| FMR LLC | 17,435,000 | $11,397,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| MORGAN STANLEY | 1,601,000 | $1,036,000 | 0.00% |